Lauren Averett Byers, MD, on ABBV-706 in Relapsed or Refractory SCLC

Lauren Averett Byers, MD, presents data on ABBV-706, an investigational antibody-drug conjugate targeting SEZ6, used alone or with the anti–PD-1 antibody budigalimab, in patients with relapsed or refractory small cell lung cancer (SCLC).

This Wire brief sits within Fusion42's coverage of Biotech.